Skip to main content

Market Overview

CBOE's Revenue Outlook Seems Healthy, Says Barclays

Share:
CBOE's Revenue Outlook Seems Healthy, Says Barclays

Barclays said the revenue outlook for CBOE Holdings, Inc (NASDAQ: CBOE) "seems healthy," despite costs set to increase in the second half of the year.

The holding company's second-quarter adjusted EPS of $0.60 compared to Barclays and the Street's $0.60. Revenues beat Barclays' expectations, but expenses fell short.

"While volumes were not as robust as 1Q levels, overall rev performance was admirable in 2Q. Market share trends look good and pricing levels appear steady," analyst Kenneth Hill wrote in a note.

"The company spoke to solid traction made on its global initiatives and many partnerships. And while each on its own may not play a significant factor in generating incremental growth; in aggregate, they should be additive to the firm over time," Hill continued.

Related Link: CBOE To List SPX Monday-Expiring Weeklys Options

Looking ahead to third quarter, the analyst is "factoring in QTD market share gains and a steady price outlook," despite volumes having tempered from the spike in June.

Moreover, the analyst expressed concerns over expenses overhauling revenue growth in the second quarter, and the worst part is that the trend is set to continue. For the full year, Barclays models 5 percent year-over-year revenue growth against 9 percent core expense growth.

As such, Hills cut his 2016 EPS estimate to $2.47 from $2.50 and 2017 EPS view to $2.63 from $2.71.

The brokerage's rule of thumb for most of its stocks covered in the sector is core expense growth of flat to up in the low single digits.

"[A]pplying that type of expense profile to CBOE (i.e. assuming flat core expense growth, all else equal) would generate an additional 12–13c of EPS on our $2.47 estimate, before considering revenue offsets though," Hill added.

Hill maintains his Underweight rating and $53 price target on the stock.

At the time of writing, shares of CBOE were down 0.41 percent to $68.51.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for CBOE

DateFirmActionFromTo
May 2021Argus ResearchMaintainsBuy
May 2021Deutsche BankMaintainsBuy
May 2021OppenheimerMaintainsOutperform

View More Analyst Ratings for CBOE
View the Latest Analyst Ratings

 

Related Articles (CBOE)

View Comments and Join the Discussion!

Posted-In: BarclaysAnalyst Color Earnings News Price Target Reiteration Analyst Ratings Movers

Latest Ratings

StockFirmActionPT
FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com